Agile’s patch can be an elegant remedy to meet the promise of contraceptive patch technology. Earlier this October, Agile announced the completion of individual enrollment ahead of plan in its pivotal, Phase 3 NEW CHOICE Research of AG200-15. Dr. Marie Foegh, Chief Medical Vice and Officer President, Clinical Development and Study of Agile Therapeutics, stated, The reported Phase 2 results demonstrate AG200-15 delivers a dose of estrogen sufficiently low to avoid increased risk of adverse events, but nonetheless effective in preventing unwanted episodes of breakthrough bleeding. This creativity is thought by us, delivering the right dosage of estrogen in combination with levonorgestrel can address women’s desire to have greater safety, convenience and ease of compliance in their selection of hormonal contraception.Conclusions Perifosine demonstrated antitumor activity in a number of gastric malignancy cell lines. Furthermore, perifosine improved the antitumor activity of 5-FU in elements of the cell lines – including 5-FU resistant cell lines. 5-FU is the energetic metabolite of the prodrug Xeloda, which is approved for the treating advanced gastric cancer in lots of countries including Korea and Japan. Poster #640: Entitled The Akt inhibitor Perifosine strongly enhances the antitumor and antivascular activity of CD34+ cells engineered expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand , Arianna Giacomini, Silvia L. Locatelli, Marco Righi, Loredana Cleris, Paolo D.